Kazia Therapeutics Ltd (KZIA)
$0.4
Performance
- $0.40$0.41$0.40
0.38%
Downside
Day's Volatility :3.92%
Upside
3.56%
- $0.19$1.58$0.40
53.35%
Downside
52 Weeks Volatility :88.19%
Upside
74.68%
Returns
| Period | Kazia Therapeutics Ltd | Index (Russel 2000) |
|---|---|---|
3 Months | -27.84% | 0.0% |
6 Months | 31.14% | 0.0% |
1 Year | -41.65% | 0.0% |
3 Years | -96.17% | -21.9% |
Highlights
Market Capitalization | 13.5M |
Book Value | $0.2 |
Earnings Per Share (EPS) | -0.37 |
Wall Street Target Price | 1.91 |
Profit Margin | 0.0% |
Operating Margin TTM | -9.999999999E7% |
Return On Assets TTM | -46.42% |
Return On Equity TTM | -186.37% |
Revenue TTM | 560.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 35.6% |
Gross Profit TTM | 555.0 |
EBITDA | -17.5M |
Diluted Eps TTM | -0.37 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 377.5%
Technicals Summary
Sell
Neutral
Buy
Kazia Therapeutics Ltd is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Kazia Therapeutics Ltd | 18.41% | 31.14% | -41.65% | -96.17% | -87.98% |
 Regeneron Pharmaceuticals, Inc. | -12.04% | 13.03% | 20.22% | 83.59% | 233.83% |
 Novo Nordisk A/s | -12.51% | -3.12% | 18.42% | 134.59% | 356.57% |
 Alnylam Pharmaceuticals, Inc. | 4.79% | 92.5% | 69.4% | 36.33% | 250.43% |
 Vertex Pharmaceuticals Incorporated | -0.94% | 22.01% | 29.63% | 166.72% | 175.25% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Kazia Therapeutics Ltd | NA | NA | NA | 0.0 | -1.86 | -0.46 | NA | 0.2 |
Regeneron Pharmaceuticals, Inc. | 26.87 | 26.87 | 1.38 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.83 | 40.83 | 1.84 | 3.37 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.43 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.58 | 0.33 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Kazia Therapeutics Ltd | Buy | $13.5M | -87.98% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $111.9B | 233.83% | 26.87 | 32.04% |
Novo Nordisk A/s | Buy | $535.2B | 356.57% | 40.83 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $36.5B | 250.43% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $125.1B | 175.25% | 32.84 | -4.74% |
Insights on Kazia Therapeutics Ltd
Decreasing Revenue
Revenue is down for the last 2 quarters, 555.0 → 5.0 (in $), with an average decrease of 99.1% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -3.43M → -8.82M (in $), with an average decrease of 64.1% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 68.5% return, outperforming this stock by 109.3%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 35.8% return, outperforming this stock by 132.0%
Institutional Holdings
Morgan Stanley - Brokerage Accounts
0.60%BNP Paribas Arbitrage, SA
0.19%Susquehanna International Group, LLP
0.12%Virtu Financial LLC
0.12%UBS Group AG
0.07%Rhumbline Advisers
0.05%
Company Information
innovative. focused. agile. kazia therapeutics is an agile, oncology-focused biotechnology company, based in sydney, australia. we have two clinical staged drug development candidates and an early stage discovery program, across a range of oncology indications. our lead program is gdc-0084, a small molecule inhibitor of the pi3k / akt / mtor pathway, which is being developed to treat glioblastoma multiforme, the primary and most aggressive form of brain cancer. licensed from genentech in late 2016, gdc-0084 is anticipated to enter phase ii clinical trials in 2017. trxe-002-1, or cantrixil is kazia’s second drug development candidate under development as a treatment for ovarian cancer. the chemotherapeutic is currently undergoing a phase 1 clinical trial in hospitals across australia and the united states. initial data on this trial is expected to be reported early in 2018. kazia therapeutics is trading under the following tickers: asx: kza nasdaq: kzia for more information, please visi
Organization | Kazia Therapeutics Ltd |
Employees | 0 |
CEO | Dr. John Edwin Friend II, M.D. |
Industry | Health Technology |
Discover More
Kraneshares Msci China All Shares Index Etf
$0.40
-0.84%
Xtrs Low Beta Hi Yield Etf
$0.40
-0.84%
Hometrust Bancshares Inc
$0.40
-0.84%
Pmv Adaptive Risk Parity Etf
$0.40
-0.84%
Precigen Inc
$0.40
-0.84%
Hitek Global Inc
$0.40
-0.84%
Arrow Dwa Country Rotation Etf -
$0.40
-0.84%
Oneascent Core Plus Bond Etf
$0.40
-0.84%
Short Dow30 Proshares
$0.40
-0.84%